Fluidia | Mamacrowd

TAX Bonus

Innov STARTUP

Watch the video

Fluidia

Biotech

The innovative method for the early diagnosis of cancer

Professional Investor

Professional Inv.

min: 150.000 €

max: 500.000 €

78 Investments

168.650 €

78 Paid

168.650 €

Minimum goal

150.000 €

Minimum Order

500,00 €

Pre-Money

2.000.000 €

22.06.2018

Closed

The content of this page has been translated automatically

Project

Fluidia is an innovative startup, operating in the life sciences & medical devices sectors, which aims to revolutionize the molecular diagnostics of cancer and other widespread diseases through an innovative, patented and scalable technology.

Currently there is no rapid, non-invasive and inexpensive test for the early screening of kidney, lung and colorectal cancer; Fluidia wants to respond to this need through the R/pR test, a simple test that allows the determination of the whole and modified form of the Raf Kinase Inhibitor Protein (RKIP) in biological fluids.
Modified proteins are indeed a promising new class of biomarkers that are more specifically associated with the onset and progression of numerous diseases. To date, quantitative assessment of these molecules can be achieved by Mass Spectrometry (MS). However, this approach is very expensive, as it requires highly qualified personnel and sophisticated instrumentation, and is difficult to standardize among different laboratories due to the lack of shared protocols.

The Fluidia entrepreneurial project stems from the need to develop a quantitative method, independent of MS, useful for an easy, rapid and economic evaluation of proteins in both native and modified forms.
An example of a modified protein is phospho-RKIP, a marker described in association with the development of several cancers. The combined assay of RKIP/pRKIP, directly in biological fluids, is therefore a very reliable tool for obtaining early diagnosis.

perche-investire-in-fluidia

Want to find out more about this project?

Do you already have an account?

The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.